Pediatric Infection and Vaccine

  • 제24권1호
  • /
  • Pages.16-22
  • /
  • 2017
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지
DOI QR코드

DOI QR Code

단일 병원에서 2013-2015년에 유행한 인플루엔자 A형과 B형의 임상 양상 및 치료반응의 차이

Differences in Clinical Manifestations and Treatment Responses in Influenza Type A and B in a Single Hospital during 2013 to 2015

  • 이상민 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 박상규 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 김지현 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 이정하 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 나소영 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 김도현 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 강은경 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 조성민 (동국대학교 의과대학 일산병원 소아청소년과) ;
  • 김희섭 (동국대학교 의과대학 일산병원 소아청소년과)
  • Lee, Sang Min (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Park, Sang Kyu (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Kim, Ji Hyun (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Lee, Jung Ha (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Na, So Young (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Kim, Do Hyun (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Kang, Eun Kyeong (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Cho, Sung Min (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
  • Kim, Hee Sub (Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine)
  • 투고 : 2016.07.30
  • 심사 : 2016.10.12
  • 발행 : 2017.04.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 인플루엔자 A형과 B형의 임상 양상이나 항바이러스제에 대한 치료반응에 차이가 있을 것이라는 가정에 따라 본 연구를 시행하였다. 방법: 2013년 10월부터 2015년 5월까지 인플루엔자 감염으로 동국대학교 일산병원에 입원한 환자를 대상으로 인플루엔자 임상 양상, oseltamivir의 복용 시간 및 인플루엔자 유형에 따른 치료반응의 차이를 조사하였다. 결과: 총 환자는 138명(남 69명, 여 69명)이고 평균 나이는 $3.5{\pm}4.0$세였다. 동반 질환으로 A형에서는 크룹(19.2% vs. 1.7%, P=0.001)이, B형에서는 근육염(0% vs. 6.7%, P=0.021)과 장염(29.5% vs. 46.7%, P=0.038)이 더 자주 발병하였다. Oseltamivir의 투약 시점과 투약 후 발열 시간을 비교하면 열 발생 2일 이내 투약한 환자군이 다른 군에 비해 전체 발열 기간이 유의하게 짧았다. Oseltamivir 복용 후 발열이 지속된 시간은 A형이 $16.0{\pm}19.1$시간, B형이 $28.9{\pm}27.9$시간으로 A형의 발열이 더 빨리 호전되었다(P=0.006). 결론: 인플루엔자는 A형과 B형에 있어서 동반되는 질환과 항바이러스제의 치료반응은 차이가 있을 수 있으며, oseltamivir 투약은 열 발생 2일 이내에 복용하는 것이 중요하다.

Purpose: We suspect there is a difference in the clinical manifestations and treatment response to antiviral drugs for influenza A and B. This study was conducted to investigate this difference. Methods: We collected information on pediatric patients, infected with the influenza virus, admitted to Dongguk University Ilsan Hospital from October 2013 to May 2015. We investigated the clinical manifestations of influenza and differences in treatment response to oseltamivir treatment for the two types of influenza. Results: A total of 138 patients were included. The mean age was $3.5{\pm}4.0$ years. When comparing the diseases associated with influenza A and B, croup (19.2% vs. 1.7%, P=0.001) was more common with influenza A infection. Myositis (0% vs. 6.7%, P=0.021) and gastroenteritis (29.5% vs. 46.7%, P=0.038) were more common with influenza B infection. When comparing the total fever duration from the start of oseltamivir administration, patients treated with oseltamivir within 2 days of fever had the shortest duration. Among the patients treated with oseltamivir, the duration of fever, after the start of oseltamivir treatment, for was shorter for influenza A infection than for influenza B infection ($16.0{\pm}19.1$ hours vs. $28.9{\pm}27.9$ hours, P=0.006). Conclusions: There appear to be differences in the accompanying diseases and antiviral medication responses between the two types of influenza. It is important to administer oseltamivir within 2 days of fever.

키워드

참고문헌

  1. Kim MS, Sung HW, Bae EY, Han SB, Jeong DC, Kang JH. The clinical characteristics of influenza B infection during the 2011-2012 influenza season. Korean J Pediatr Infect Dis 2013;20:89-97. https://doi.org/10.14776/kjpid.2013.20.2.89
  2. Choi JW, Cho HJ, Kim HM, Hahn S. Clinical and laboratory findings of the 2012 winter seasonal influenza A and B outbreak at a single institution. Korean J Pediatr Infect Dis 2014;21:1-8. https://doi.org/10.14776/kjpid.2014.21.1.1
  3. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007;44:197-202. https://doi.org/10.1086/509925
  4. Kang TG, Kim MJ, Kim BG, An HS, Yun HJ, Choi EJ, et al. Comparisons of clinical features among influenza A (H1N1) and seasonal influenza A and B during 2009 to 2010 at a single institution. Pediatr Allergy Respir Dis 2011;21:269-76. https://doi.org/10.7581/pard.2011.21.4.269
  5. Daley AJ, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health 2000;36:332-5. https://doi.org/10.1046/j.1440-1754.2000.00533.x
  6. Noma S. Acute myositis associated with influenza. Nihon Rinsho 2006;64:1921-3.
  7. Youn SE, Chun JH, Lee KS, Rha YH, Choi SH. Clinical characteristics of influenza B virus in children and the efficacy of oseltamivir: data from two university hospitals. Korean J Pediatr Infect Dis 2014;21:199-206. https://doi.org/10.14776/kjpid.2014.21.3.199
  8. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50. https://doi.org/10.1016/S0140-6736(00)02288-1
  9. Mitamura K, Sugaya N, Nirasawa M, Shinjoh M, Takeuchi Y. Effectiveness of oseltamivir treatment against influenza type A and type B infection in children. Kansenshogaku Zasshi 2002;76:946-52. https://doi.org/10.11150/kansenshogakuzasshi1970.76.946
  10. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-92. https://doi.org/10.1128/AAC.00555-08
  11. Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 2013;100:520-34. https://doi.org/10.1016/j.antiviral.2013.08.023
  12. Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, et al. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 2012;429:51-6. https://doi.org/10.1016/j.bbrc.2012.10.095
  13. Ministry of Food and Drug Safety. Proven domestic influenza vaccine safety, efficacy and effectiveness [Internet]. Cheongju: Ministry of Food and Drug Safety; 2015 [cited 2016 Dec 22]. Available from: http://www.mfds.go.kr/index.do?mid=675&seq=26946&cmd=v.
  14. Ki HO, Kim IH, Cho EH, Kang MG, Chu H. Korean influenza sentinel surveillance report, 2013-2014. Public Health Wkly Rep 2014;7:1089-98.
  15. Ki HO, Kim IH, Cho EH, Kang MG, Chu H, Lee JY. Korean influenza sentinel surveillance report, 2014-2015. Public Health Wkly Rep 2015;8:1096-106.